Abridge vs Heidi Health (2026)
The two run different maps. Abridge is the US enterprise reference standard: Best in KLAS for Ambient AI in 2025 and 2026, the category's largest peer reviewed study with 1,306 Kaiser Permanente clinicians in NEJM AI, native Epic depth, and Linked Evidence tracing every sentence of a note back to source audio. Heidi's claim is breadth: a reported 2.5 million consults a week across 110 languages, 190 countries, and more than 200 specialties, with published pricing from a free tier and a product expanding into cited decision support through Heidi Evidence. The procurement catch sits on Heidi's side: an organization wide Business Associate Agreement and push to chart integration are both reported as gated to upper tiers, so a US buyer should evaluate the tier they would actually sign. If your failure mode is auditable evidence and structured Epic workflow in a US health system, start with Abridge. If your failure mode is languages, geographies, or needing a price without a sales call, start with Heidi.
- The evidence gap is the widest in this pairing: Abridge holds the category's largest independent peer reviewed study and consecutive Best in KLAS awards, while Heidi's clinical evidence grades C with no accuracy study against ground truth retrieved.
- Structured workflow, not copy and paste: native embedding across Epic Haiku, Canto, and Hyperdrive with bidirectional sync, extending into structured orders and real time prior authorization, where Heidi's push to chart is reported as gated to the Practice tier upward.
- Compliance posture is unconditional: Linked Evidence gives sentence level verification before signing, and no BAA tier gates apply, against Heidi's C grade on the HIPAA axis for gating the organization wide BAA to upper tiers.
- Language and geography decide it: a reported 110 languages across 190 countries and more than 200 specialties, the broadest coverage in the category, against Abridge's stated 28 plus languages and US enterprise center of gravity.
- You need a price without a sales call: a free tier with unlimited transcription and a published Clinician tier at $150 per user per month billed annually, where Abridge publishes nothing and offers no individual plan.
- The platform is expanding under you: Heidi Evidence surfaces cited clinical decision support from BMJ, NICE, and HealthPathways at the point of care, and Heidi Comms coordinates patient calls, on a company that raised a $65 million Series B in late 2025.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Abridge and Heidi Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Abridge | Heidi Health |
|---|---|---|
| Primary category | Ambient Scribes | Ambient Scribes |
| Founded | 2018 | Not recorded |
| Headquarters | Pittsburgh, Pennsylvania | Melbourne, Australia |
| Website | abridge.com | heidihealth.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Abridge its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model Supply Chain Disclosure. Set against Heidi Health, Abridge grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Heidi Health its top capability grade on several axes, including AI Centrality, AI Safety and PHI Stewardship and Security Certifications and Trust Center. Set against Abridge, Heidi Health grades higher on several axes, including AI Safety and PHI Stewardship, AI Liability and Recourse and Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Abridge or Heidi Health?
On the axes where the AI Health Index separates them, Abridge grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure, and Heidi Health grades higher on several axes, including AI Safety and PHI Stewardship, AI Liability and Recourse and Deployment Model and Data Residency. Abridge leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Abridge and Heidi Health differ most?
The widest separation the AI Health Index records between Abridge and Heidi Health is on Model Supply Chain Disclosure, where Abridge grades A and Heidi Health grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Abridge and Heidi Health grade the same?
The AI Health Index grades Abridge and Heidi Health the same on several axes, including AI Centrality, Security Certifications and Trust Center and FDA and Regulatory Status. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Volume figures for both vendors are vendor published, including Heidi's 2.5 million weekly consults and Abridge's 250 plus health systems; Abridge's evidence grade reflects the scale and venue of the Kaiser Permanente study rather than a re verification of its findings. Heidi's clinical evidence grades C on this index, and third party review is unusually candid about limits, including that multi problem visits document less reliably than single problem encounters.
Two Heidi tier gates matter for US buyers: the organization wide BAA and EHR write back are both reported as available only from the Practice tier upward; confirm coverage on the contracted tier before deployment. Heidi's pricing was restructured in February 2026 and sources conflict on some tier amounts. Abridge publishes no pricing; a third party estimate near $2,500 per clinician per year is recorded as an estimate.